Anti-inflammatory effects of locally applied enzyme-loaded ultradeformable vesicles on an acute cutaneous model

Journal of Microencapsulation

Volumn 26, Issue 7, 2009, Pages 649-658

  Simões, Sandra ^a   Marques, Cláudia ^a   Cruz, Maria Eugénia ^a   Figueira Martins, Maria Bárbara ^a  

^a INETI   (Portugal)

Author keywords

Antioxidant enzymes; Arachidonic acid mouse ear inhibition test; Catalase; Skin delivery; Superoxide dismutase

Indexed keywords

ARACHIDONIC ACID; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; ETOFENAMATE; INDOMETACIN; LIPOSOME; PIROXICAM; REUMON LOCAO; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; EAR DISEASE; EAR EDEMA; FEMALE; LIPID VESICLE; MOUSE; NONHUMAN; PROPHYLAXIS; PROTEIN TRANSPORT; SKIN PENETRATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CATALASE; MICE; MODELS, BIOLOGICAL; SKIN; SUPEROXIDE DISMUTASE;

EID: 70449338210     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652040802630403     Document Type: Article

References (53)

1. Beers Jr RF, Sizer IW. 1952. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 195:133-140.
2. Brown MC, Martin GP, Jones SA, Akomeah FK. 2006. Dermal and transdermal drug delivery systems: Current and future prospects. Drug Del 13:175-187.
3. Burchardt ER, Müller-Peddinghaus R. 1997. Antiedematous effects of combination therapies with the leukotriene synthesis inhibitor BAYX 1005 in the arachidonic acid induced mouse ear inflammation test. Prostaglandins Leukotrienes Essential Fatty Acids 56:301-306.
4. Cash CD. 1997. Are the reactive oxygen-derived species (ROS) interactive porperties of the many therapeutic drugs from various categories pertinent to their beneficial effects? Gen Pharmac 28:169-175.
5. Cevc G. 1997. Drug delivery across the skin. Exp Opin Invest Drugs 6:1887-1937.
6. Cevc G, Blume G. 1992. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta 1104:226-232.
7. Cevc G, Blume G. 2001. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Biochim Biophys Acta 1514:191-205.
8. Cevc G, Blume G, Schätzlein A. 1997. Transfersomes mediated transepidermal delivery improves the regio-specificity and biological activity of corticosteroids in vivo. J Contr Rel 45:211-226.
9. Cevc G, Blume G, Schätzlein A, Gebauer D. 1996. The skin: A pathway for systemic treatment with patches and lipid-based agent carriers. Adv Drug Deliv Rev 18:349-378.
10. Cevc G, Schätzlein A, Richardsen H. 2002. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers intact. Evidence from double label CLSM experiments and direct size measurements. Biochim Biophys Acta 1564:21-30.
11. Cevc G, Vierl U. 2007. Spatial distribution of cutaneous microvasculature and local drug clearance after drug application on the skin. J Contr Rel 118:18-26.
12. Choi MJ, Maibach HI. 2005. Elastic vesicles as topical/transdermal drug delivery systems. Int J Cosmet Sci 27:211-221.
13. Corvo ML, Boerman OC, Oyen WJ, Jorge JC, Cruz ME, Crommelin DJ, et al. 2000. Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: In vivo fate and therapeutic activity in an inflammation model. Pharm Res 17:600-606.
14. Corvo ML, Boerman OC, Oyen WJG, Van Bloois L, Cruz MEM, Crommelin DJA, et al. 1999. Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo fate in a rat model of adjuvant arthritis. Biochim Biophys Acta 1419:325-334.
15. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. 2001. Antioxidant therapy: A new pharmacological approach in shock, inflammation, and ischemia/ reperfusion injury. Pharmacol Rev 53:135-159.
16. Edeas MA, Peltier E, Claise C, Khalfoun Y, Lindenbaum A. 1996. Immunocytochemical study of uptake of exogenous carrier-free copper-zinc superoxide dismutase by peripheral blood lymphocytes. Cell Mol Biol 42:1137-1143.
17. El Maghraby GMM, Campbell M, Finnin BC. 2005. Mechanisms of action of novel skin penetration enhancers: Phospholipid versus skin lipid liposomes. Int J Pharm 305:90-104.
18. Fang J-Y, Hwang T-L, Huang Y-L. 2006. Liposomes as vehicles for enhancing drug delivery via skin routes. Curr Nanosci 2:55-70.
19. Hamer RR, Tegeler JJ, Kurtz ES, Allen RC, Bailey SC, Elliott ME, et al. 1996. Dibenzoxepinone hydroxylamines and hydroxamic acids: Dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity. J Med Chem 39:246-252.
20. Heyneman CA, Lawless-Liday C, Wall GC. 2000. Oral versus topical NSAIDs in rheumatic diseases: A comparison. Drugs 60:555-574.
21. Horizoe T, Nagakura N, Chiba K, Shirota H, Shinoda M, Kobayashi N, et al. 1998. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model. Inflamm Res 47:375-383.
22. Jadot G, Vaille A, Maldonado J, Vanelle P. 1995. Clinical pharmacokinetics and delivery of bovine superoxide dismutase. Clin Pharmacokinet 28:17-25.
23. Jubeh TT, Antler S, Haupt S, Barenholz Y, Rubinstein A. 2005. Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine. Molec Pharm 2:2-11.
24. Jubeh TT, Nadler-Milbauer M, Barenholz Y, Rubinstein A. 2006. Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD. J Drug Target 14:155-163.
25. Kim B-J, Kim J-H, Heo M-Y, Kim H-P. 1998. Antioxidant and anti-inflammatory activities of the mung bean. Cosmetics Toiletries 113:71-74.
26. Kimura K. 1997. Mechanisms of active oxygen species reduction by nonsteroidal anti-inflammatory drugs. Int J Biochem Cell Biol 29:437-446.
27. Lefaix J-L, Delanian S, Leplate J-J, Tricaud Y, Martin M, Nimrod A, et al. 1996. Successful treatment of radiation-induced fibrosis using Cu,Zn- SOD and Mn-SOD: An experimental study. Int J Radiat Oncol Biol Phys 35:305-312.
28. Lloret S, Moreno JJ. 1995. Effects of an anti-inflammatory peptide (antiflammin 2) on cell influx, eicosanoid biosynthesis and oedema formation by arachidonic acid and tetradecanoyl phorbol dermal application. Biochem Pharmacol 50:347-353.
29. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
30. Müller-Peddinghaus R, Kohlsdorfer C, Theisen-Popp P, Fruchtmann R, Perzborn E, Beckermann B, et al. 1993. BAY X1005, a new inhibitor of leukotriene synthesis: In vivo inflammation pharmacology and pharmacokinetics. J Pharmacol Exp Therap 267:51-57.
31. Marques CM, Simões SI, Cruz ME, Cevc G, Martins MB. Formulation of catalase-loaded ultraflexible vesicles for transdermal delivery, Proceedings of the 8th Liposome Research Days Conference; 2002. p 105.
32. Mizushima Y, Hoshi K, Yanagawa A, Takano K. 1991. Topical application of superoxide dismutase cream. Drugs Exp Clin Res 17:127-131.
33. Muzykantov VR. 2001. Targeting of superoxide dismutase and catalase to vascular endothelium. J Contr Rel 71:1-21.
34. Prausnitz MR. 1997. Reversible skin permeabilization for transdermal delivery of macromolecules. Crit Rev Ther Drug Carrier Syst 14:455-483.
35. Puignero V, Queralt J. 1997. Effect of topically applied cyclosporin A on arachidonic acid (AA)- and tetradecanoylphorbol acetate (TPA)- induced dermal inflammation in mouse ear. Inflammation 21:357-369. (Pubitemid 27367836)
36. Rother M, Lavins BJ, Kneer W, Lehnhardt K, Seidel EJ, Mazgareanu S. 2007. Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: Multicentre randomised controlled trial. Ann Rheum Dis 66:1178-1183.
37. Simões SI, Marques CM, Cruz MEM, Cevc G, Martins MB. Study of the tissue distribution of SOD-loaded transfersomes. Proceedings of the 8th Liposome Research Days Conference; 2002. p 67.
38. Simões SI, Marques CM, Cruz MEM, Cevc G, Martins MBF. Novel carriers for antioxidant enzymes: Anti-inflammatory effects on arachidonic acid induced ear edema in mice. Barrier Function of Mammalian Skin, Bristol-Rhode Island, USA; 2003.
39. Simões SI, Martins MBF, Cruz MEM, Cevc G. Effects of transfersomal Cu/ Zn-superoxide dismutase on arachidonic acid-induced ear edema in mice. Proceedings of Cosming; 1998. p 266.
40. Simões SI, Richardsen HC, Martins MB, Cruz ME, Cevc G. Superoxide dismutase delivery through the narrow pores in skin models by flexible lipid aggregates, Proceedings of The III Spanish-Portuguese Conference on Controlled Drug Delivery; 1998. p 49.
41. Simões SID. Preparation and characterization of enzyme-loaded Transfersomes. PhD thesis. 2005. Chapter 4.
42. Simões SI, Delgado TC, Lopes RM, Jesus S, Ferreira AA, Morais JA, et al. 2005. Developments in the rat adjuvant arthritis model and its use in therapeutic evaluation of novel non-invasive treatment by SOD in Transfersomes. J Contr Rel 103:419-434.
43. Simões SI, Marques CM, Cruz MEM, Cevc G, Martins MBF. 2004. The effect of cholate on solubilisation and permeability of simple and protein loaded phosphatidylcholine/sodium cholate mixed aggregates designed to mediate transdermal delivery of macromolecules. Eur J Pharm Biopharm 58:509-519.
44. Simões SI, Tapadas JM, Marques CM, Cruz MEM, Martins MBF, Cevc G. 2005. Permeabilisation and solubilisation of soybean phosphatidylcholine bilayer vesicles, as membrane models, by polysorbate, Tween 80. Eur J Pharmaceut Sci 26:307-317.
45. Szoka F, Olson F, Heath T, Vail W, Mayhew E, Papahadjopoulos D. 1980. Preparation of unilamellar liposomes of intermediate size (0.1-0.2 mumol) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim Biophys Acta 60:559-571.
46. Thomson PD, Till GO, Woolliscroft JO, Smith DJ, Presad J. 1990. Superoxide dismutase prevents lipid peroxidation in burned patients. Burns 16:406-408.
47. Trenam CW, Dabbagh AJ, Morris CJ, Blake DR. 1991. Skin inflammation induced by reactive oxygen species (ROS): An in vivo model. Br J Dermatol 125:325-329.
48. Turrens JF, Crapo JD, Freeman BA. 1984. Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. J Clin Invest 73:87-95.
49. Vorauer-Uhl K, Furnschlief E, Wagner A, Ferko B, Katinger H. 2001. Topically applied liposome encapsulated superoxide dismutase reduces postburn wound size and edema formation. Eur J Pharm Sci 17:63-67.
50. Walther FJ, David-Cu R, Lopez SL. 1995. Anti-oxidant-surfactant liposomes mitigate hyperoxic lung injury in premature rabbits. Am J Physiol 269:L613-L617.
51. Way JC. 2002. Second-generation protein drugs: Children of the revolution. Drug Discov World 4:62-68.
52. Yabe Y, Nishikava M, Tamada A, Takakura Y, Hashida M. 1999. Targeted delivery and improved therapeutic potential of catalase by chemical modification: Combination with superoxide dismutase derivatives. J Pharmacol Exp Therap 289:1176-1184.
53. Young JM, De Young LM, 1989. Cutaneous models of inflammation for the evaluation of topical and systemic pharmacological agents. In: Spector J, Back N, editors. Pharmacological methods in the control of inflammation. New York: Alan R Liss. pp 215-231.